Sarepta Shows Promise in Rare Disease Treatment Trials

After a difficult year, biotech company Sarepta Therapeutics is bouncing back with early clinical trial results showing two new muscular dystrophy treatments appear safe and effective.

The promising data offers hope for patients with rare muscle-wasting diseases who desperately need new treatment options.